Kornimate/medical-research-clean huggingface dataset:
effects of allergic rhinitis on the nasal/sinus microbiome

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to find out if the bacteria present in the nose or sinuses of people with seasonal allergies changes during their allergy season. another purpose of this study is to see if the bacteria present in the nose and sinuses of non-allergic people are the same as allergic people before the allergy season and if it changes during the season. many bacteria are difficult to grow in the laboratory so the investigators are using analysis of dna (the genetic material in cells) of the bacteria in the nose and sinus to find them. the investigators will be testing dna of the bacteria only and not of the human subjects taking part in this study. this research is being done to help us understand how allergy affects bacteria in the nose and sinuses.


Eligibility criteria:
inclusion criteria 1. males and females between 18 and 55 years of age. 2. history of tree and/or grass allergic rhinitis for at least 2 years (allergic subjects) or no allergy history at all (normal controls). 3. for allergic subjects, a positive skin test to trees and/or grass antigen within prior 12 months. for non-allergic subjects, negative skin tests to common allergens in the chicago area. exclusion criteria 1. respiratory disease other than allergic rhinitis, allergic conjunctivitis and mild asthma. 2. use of nasal steroids, antihistamines in the last 4 weeks. 3. upper respiratory infection, sinusitis less than 2 weeks before screening. 4. structural nasal abnormalities or nasal polyps on examination, nasal ulcer, frequent nose bleeding, recent nasal surgery or nasal trauma (within 90 days). 5. participation in other investigational therapy in the last 30 days. 6. any systemic disorder or medication interfering with the study. 7. undergoing allergen desensitization therapy. 8. not willing to give informed consent 9. inability to understand the nature and requirements of the study, or to comply with the study procedures. 10. any social or medical condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
characterizing and comparing the profile of microorganisms from specific body sites and environmental surfaces in newly disinfected patient rooms

Conditions: Bacterial Infection

Summary: overall aim: to describe and to assess the change in the temporal profile and transmission of microorganisms between patients and environmental surfaces after admission into a newly disinfected room. study activities: investigators will prospectively and concurrently perform microbiological sampling of body sites (nose, throat, axillae, perineal and wounds) high touch surfaces (e.g. bedside rail, bed surface, toilet seat, iv pump and tray table) for consented adult patients admitted to freshly cleaned patient rooms. the microbiological sampling of body sites is already performed in many units of the hospital as standard of care. infection and readmission related data from enrolled patients will be collected for upto 1 year after enrollment. data analysis: standard surveillance for hospital-acquired infections will be performed by the infection control group of the hospital. the identity and the nature of micro-organisms colonizing the high touch surfaces of rooms and of patient's body sites will be determined and compared. risks involved is no more than minimal risk.


Eligibility criteria:
inclusion criteria: * eligible patients who provide informed consent. exclusion criteria: * pediatric patients under 18 years of age, * patients who cannot or do not provide consent

Keywords: bacterial colonization
the effect of acupressure in non-breastfeeding mothers after preterm cesarean delivery

Conditions: Acupressure; Breastfeeding

Summary: the effect of acupressure in non-breastfeeding mothers after preterm cesarean delivery

one of the frequently encountered problems in breastfeeding is insufficient lactation. numerous integrative treatments support to overcome this problem. this randomized controlled experimental study will conduct to determine the effect of acupressure on lactation in non-breastfeeding mothers following preterm caesarean delivery. the sample of the study will comprise of 64 mothers (32 acupressure-experimental and 32 control group), who will randomly select from among the primipara mothers of premature newborns delivered through cesarean section at dursun odabaş medical center of van yüzüncü yıl university. before the implementation, the depression-anxiety-stress scale and the richard campbell sleep quality scale will apply. in post-operative three days, 15-minute acupressure will implement in the morning/evening, for acupressure-group mothers and pump milking will apply; control group mothers will only milked in mornings and evenings. lactation symptoms will evaluate with visual analog scale and acupressure satisfaction with analog patient satisfaction scale, and milk quantities will record.

Eligibility criteria:
inclusion criteria: * mothers between the ages of 19-35, * mothers who gave birth by cesarean operation, * mothers who gave birth before 37th week of pregnancy, * primiparous mothers, * mothers whose baby is lying in nicu, * mothers who do not have any chronic diseases, * mothers who do not use breast milk enhancing drugs, vitamins and supplements, * mothers who do not have any anotomic disorder in the breast, * mothers who cannot breastfeed, * mothers who do not have any injured skin, fracture, swelling or muscle pain, especially in the little finger. * mothers without literacy problems, mental disabilities and communication problems, * mothers living within the borders of the province of van, * mothers who agree to participate in the study. exclusion criteria: * mothers of premature newborns who cannot be fed breast milk, * mothers who are multiparous, * mothers with chronic disease, * mothers who have a condition preventing milking, * mothers whose language is insufficient in understanding and speaking turkish, * mothers who have breast abscess problems, * mothers who have babies with congenital anomalies, * they are mothers who do not volunteer to participate in the study

Keywords: acupressure, breastfeeding
middle ear pressure disregulation after tympanostomy tube insertion

Conditions: Otitis Media With Effusion

Summary: this study will determine if the investigators can use certain tests (eustachian tube function tests and gas exchange tests) to predict whether or not a child who had tubes surgically placed in their eardrum because of middle-ear disease will redevelop the disease again after the tubes quit working.

this study will enroll children 3-6 years of age with tympanostomy tubes inserted for otitis media with effusion (ome)and measure middle ear gas demand, middle ear volume and eustachian tube function longitudinally between the time of tube insertion and extrusion/nonfunctioning. the data will be used to test the hypotheses that: gas transfer across the middle ear mucosa decreases in phase with resolution of middle ear inflammation and effusion; gas transfer across the middle ear mucosa is increased by an episode of otorrhea; eustachian tube function is unaffected by tympanostomy tube insertion, and measurement of eustachian tube function and trans-middle ear mucosa gas transfer predicts disease recurrence and presentation after tube extrusion/nonfunctioning. the results of these studies will be used to support or refute tested components of existing models of middle ear pressure-regulation and to develop test protocols for risk assignments with respect to disease recurrence in individual ears after tympanostomy tube extrusion/nonfunctioning.

Eligibility criteria:
inclusion criteria: * 3-6 years old * history of chronic otitis media with effusion(ome) * scheduled or within 6 weeks of tube insertion * ome at entry or surgery * generally good health exclusion criteria: * cleft palate or other syndromes predisposing to om * history of recurrent acute otitis media only * history of complications of om or its treatment * unable to cooperate for testing

Keywords: otitis media tympanostomy tube eustachian tube function gas exchange tympanostomy tubes
quality of life and sjögren syndrome

Conditions: Xerostomia; Hyposalivation; Quality of Life; Sjogren's Syndrome

Summary: the aims of this study are: to compare salivary ph changes and stimulation efficacy of two different gustatory stimulants of salivation (gsss) in patients with primary sjögren syndrome (pss); to evaluate primary sjögren syndrome (pss) impact and gustatory stimulants of salivary secretion (gsss) on oral health related quality of life measured by a portuguese version of oral health impact profile-14 (ohip-14) and specific xerostomia assessment questionnaires. the products to be used are the xeros® dentaid system and a citric based mouthwash.


Eligibility criteria:
inclusion criteria: * unstimulated whole saliva secretion rate \< 0.1 ml/min * stimulated whole saliva secretion rate \> 0.2 ml/min * above 18 years of age * primary sjogren syndrome diagnostic according to the european-american consensus group exclusion criteria: * wearer of complete dental prosthesis * those who were pregnant or lactating * non-speakers of portuguese.

Keywords: xerostomia hyposalivation quality of life sjogren's syndrome
video capsule endoscopy versus colonoscopy in patients with melena and negative upper endoscopy

Conditions: Gastrointestinal Hemorrhage

Summary: acute gastrointestinal bleeding is a common medical problem. when patients with gastrointestinal bleeding present with melena (dark, tarry stool) the blood loss is usually originating in the upper gastrointestinal tract (esophagus, stomach or duodenum) and first step in evaluating the patient is an upper endoscopy; which allows direct visualization of the esophagus, stomach and duodenum. however, the cause of bleeding is located in the small bowel or colon in 20-30% of patients who present with melena. traditionally colonoscopy has been the next test preformed if upper endoscopy does not identify the cause of melena/ gastrointestinal bleeding, however less than 25% of patients who present with melena have bleeding originating in the colon, and the remainder of patients have bleeding originating in the small intestine, which can only be fully evaluated with video capsule endoscopy (a pill camera which is swallowed and takes pictures while it travels thought the small bowel and colon). currently patients only undergo video capsule endoscopy if colonoscopy does not identify the cause of bleeding. the investigators are preforming a randomized study which seeks to determine if colonoscopy or video capsule endoscopy is a better way to identify the cause of gastrointestinal bleeding in patients who present with melena and have normal findings on upper endoscopy. to do this the investigators will enroll patients who present with melena prior to their upper endoscopy and if the cause of bleeding is not identified at that time patients will be randomized to video capsule endoscopy (with the capsule being placed into the small bowel during the upper endoscopy) or next day colonoscopy.


Eligibility criteria:
inclusion criteria: • inpatients \>18 years of age presenting with lower gastrointestinal bleeding and have melenic stool exclusion criteria: * unable to provide written informed consent * a probable bleeding source is identified on upper endoscopy * pregnancy or lactation * swallowing disorder * unable to tolerate sedation or anesthesia due to medical co-morbidities * uncorrected coagulopathy (platelet count \ 2, ptt\> 2x upper limit of normal) * known or suspected gastrointestinal obstruction or stricture * cardiac pacemaker or other implanted electromedical device * contraindication to bowel preparation
identify predictors that distinguish between tofacitinib responders and non-responders based on genotype and cellular and molecular profiles from pinch biopsies, blood and stool samples

Conditions: Ulcerative Colitis

Summary: this is a prospective cohort study enrolling ulcerative colitis patients who initiate tofacitinib therapy. investigators will collect clinical data, blood and stool samples prior to initiation of tofacitinib and, at minimum, monthly after the start of therapy. they will collect tissue from colonoscopies prior to initiation of therapy and within 6 months on therapy. clinical characteristics and response to treatment will then be associated with genotype, blood immune profiles, stool microbiota, and cellular and molecular profiles of the biopsies to generate a treatment response model. using predictors identified in our model, we will then attempt to validate the model and findings with the octave (pfizer), sparc (ccf), and risk (ccf) data.


Eligibility criteria:
inclusion criteria: * total mayo score between 6 and 12 * endoscopic subscore of 2 or 3 exclusion criteria: * recent use of antibiotic therapy (\<4 weeks) * current extreme diet (parenteral nutrition, specific carbohydrate diet). * active infection or malignancy. * significant underlying liver or renal disease.
the gut microbiome in women with polycystic ovary syndrome

Conditions: PCOS; Obesity; Metabolic Syndrome

Summary: testing two different strategies for weight loss intervention and revealing possible changes in composition of gut microbiota, in order to provide more insight in the effect of dietary changes and weight loss treatments on gut microbiome in overweight and obese women with polycystic ovary syndrome (pcos). the two strategies are: * dietary advice plus myo-inositol and folic acid * dietary advice plus liraglutide, glucagon-like peptide-1 (glp-1) receptor agonist primary outcome will be weight loss. secondary outcomes are longitudinal changes in clinical features associated with pcos and metabolic syndrome, longitudinal changes in gut microbiome with interventions. subjects will be treated during 16 weeks and follow-up will take 16 weeks after stop of treatment.


Eligibility criteria:
inclusion criteria: * pcos according to rotterdam criteria * bmi ≥ 27 kg/m2 and at risk of metabolic syndrome or bmi ≥ 30 kg/m2 exclusion criteria: * pregnancy * pancreatitis (in the past) * oral contraceptive pill use * inflammatory bowel disease * auto-immune disease * immuno-modulatory drugs * antidiabetic drugs * anti-inflammatory drugs
pilot study for the evaluation of the safety and performance of the renasense system in hospitalized acute decompensated heart failure patients

Conditions: Heart Decompensation; Heart Failure, Congestive; Renal Insufficiency

Summary: the study is intended to verify the safety and assess the performance of up to 3-days treatment protocol with the renasense system in adhf patients.


Eligibility criteria:
inclusion criteria: 1. females 2. age 18-85 years 3. admitted to the hospital with a primary diagnosis of decompensated heart failure 4. estimated glomerular filtration rate (gfr)\* ≤60 ml/min and ≥20 ml/min, based on serum creatinine at initial evaluation 5. history of chronic use of oral loop diuretics (≥ 80 mg/day furosemide or equivalent) during the past 3 months 6. indication for treatment with intravenous diuretics 7. volume overload for patients with a pulmonary artery catheter, persistent volume overload will include: * pulmonary capillary wedge pressure greater than 22mmhg and one of the following clinical signs: * at least 2+ peripheral edema and/or * pulmonary edema or pleural effusions on chest x-ray for patients without a pulmonary artery catheter, persistent volume overload will include at least two of the following: * at least 2+ peripheral edema * jugular venous pressure greater than 10 cm on physical examination (or central venous pressure greater than 10 mmhg when measured) * pulmonary edema or pleural effusions on chest x-ray 8. indication for urinary catheterization 9. bnp \> 400 pg/ml at initial evaluation 10. able and willing to sign the informed consent exclusion criteria: 1. history of urinary tract infection within the last 1 month based on medical history and/or urinalysis on day of admission 2. gross hematuria, perineal hematoma or symptomatic microscopic hematuria 3. hypertension, systolic \>180 mmhg or diastolic \> 110 mmhg 4. hypotension, systolic pressure \<100 mmhg 5. status post renal denervation 6. implanted cardiac rhythm management device such as pacemakers, cardiac resynchronization therapy (crt), implantable cardioverter-defibrillator (icd) 7. suspected or known pregnancy 8. previous organ transplantation 9. life threatening condition such as severe infection, malignancy or infarction 10. subject is participating in other concurrent clinical investigation 11. diseases or conditions which, in the judgment of the investigator, preclude participation in the clinical trial
phase ii study of stereotypes and mental retardation: neurobiological basis

Conditions: Stereotyped Behavior; Mental Retardation

Summary: objectives: i. determine differences between persons with repetitive behavior disorders and matched controls on measures of motor control relevant to basal ganglia pathophysiology. ii. determine the efficacy of bromocriptine, a dopamine agonist, in the treatment of stereotyped behavior and related behavior disorders. iii. determine the efficacy of sertraline hydrochloride, a selective serotonin uptake inhibitor, in the treatment of repetitive behavior disorders. iv. identify behavioral, environmental, and biological variables with differential drug treatment response.

protocol outline: motor slowness (bradykinesia) and motor control are tested in repetitive behavior disorder patients and matched controls. group differences reflecting alterations in basal ganglia dopamine function are compared. behavioral assessments are conducted on each patient by trained observers. assessments are taken at baseline and during the maintenance phase of drug treatment described below. the efficacy of bromocriptine in the treatment of stereotypy and self-injury is determined in a randomized, double blind, placebo controlled, crossover study extending over 20 weeks. cohorts of 6 to 8 patients first enter into a single blind placebo phase, followed by double blind treatment with placebo or bromocriptine. the crossover manipulation entails a titration phase, a maintenance phase, then a final single blind placebo condition. the same experimental design is used to determine the efficacy of sertraline or placebo in the treatment of stereotypy and concomitant self injury and compulsions. duration of study is 26 weeks.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnosis of mental retardation * high rate of stereotyped behavior, such as concomitant self-injurious and compulsive behaviors * no diagnosis of tardive dyskinesia or akathisia --prior/concurrent therapy-- * no exposure to neuroleptics within 6 months prior to study --patient characteristics-- * age: 18 to 55 * hematopoietic: (for bromocriptine and sertraline treatments) no history of anemia no clinically significant hematologic disease * hepatic: (for bromocriptine and sertraline treatments) no history of hepatic abnormalities no clinically significant liver disease * renal: (for bromocriptine and sertraline treatments) no history of renal abnormalities no clinically significant renal disease * cardiovascular: (for bromocriptine and sertraline treatments) no history of hypertension no clinically significant cardiac disease * other: no history of seizure within 4 months prior to study (for bromocriptine and sertraline treatments) no history of sensitivity to ergot alkaloids (for bromocriptine treatment) no sensitivity to serotonin uptake inhibitors (for sertraline treatment) no patients with sensory deficits (for motor function assessments)

Keywords: mental retardation neurologic and psychiatric disorders rare disease stereotyped behavior
long-term clinico-radiological evolution of patients with brain lesions during infectious endocarditis

Conditions: Infectious Endocarditis

Summary: primary objective: to describe the evolution of cerebral lesions in ie patients (number of patients with abnormal cerebral mri in acute phase of ie and during follow-up).

introduction: infectious endocarditis (ie) is a rare disease (1500 cases per year in france) with a poor prognosis (20 % of mortality). neurological complications participate in the initial morbimortality but their long-term impact is poorly known. the acute neurological complications are symptomatic in approximately a quarter of patients. neurological lesions are frequently observed using systematic cerebral imaging. in the image study, systematic cerebral mri in 130 patients performed during the acute phase of ie allowed found cerebral lesion in 82 % of the patients and in 79 % of patients without neurological symptoms. the evolution of cerebral lesion, including brain micro-bleedings and their impact prognosis are not known. hypothesis: cerebral lesions detected by mri during the acute phase of infectious endocarditis may involve and may have an impact on functional prognosis. primary objective: to describe the evolution of cerebral lesions in ie patients (comparing the proportion of patients with abnormal cerebral mri in acute phase of ie and during follow-up). secondary objectives: * to compare frequency of different brain damages in acute phase of ie and during follow-up. * to analyse the relationship between functional and cognitive status and cerebral lesions. * to analyse the relationship between initial and follow-up cerebral lesions and initials characteristics (microorganisms, anticoagulation, echocardiographic characteristics, valve replacement surgery, type of valvular substitute, mycotic aneurysm embolization) * to collect plasma during follow-up of ie * to compare patient characteristics between patients who accept the functional exploration and those who patient refuse * to describe oral health and oral condition

Eligibility criteria:
inclusion criteria: * history of infective endocarditis treated in bichat claude bernard hospital * cerebral mri performed during the acute phase of endocarditis * resident in metropolitan france * 18 years old or more exclusion criteria: * refusal to participate * contra indication to mri scan * history of allergy to gadolinium * pregnancy or lactating female * lack of social security or cmu (recipient or beneficiary)

Keywords: brain damages mri infectious endocarditis